Beam Therapeutics Inc’s filing revealed that its Chief Legal Officer Bellon Christine unloaded Company’s shares for reported $30628.0 on Jan 02 ’25. In the deal valued at $24.68 per share,1,241 shares were sold. As a result of this transaction, Bellon Christine now holds 102,968 shares worth roughly $2.72 million.
Then, Cavanagh Bethany J sold 1,117 shares, generating $27,568 in total proceeds. Upon selling the shares at $24.68, the SVP, Finance and Treasurer now owns 43,814 shares.
Before that, BETHANY J. CAVANAGH bought 9,500 shares. Beam Therapeutics Inc shares valued at $240,065 were divested by the Officer at a price of $25.27 per share.
Leerink Partners upgraded its Beam Therapeutics Inc [BEAM] rating to an Outperform from a a Market perform in a research note published on November 06, 2024; the price target was increased to $39 from $27. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. H.C. Wainwright began covering BEAM with “Buy” recommendation on July 23, 2024. JP Morgan revised its rating on January 29, 2024. It rated BEAM as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of BEAM
On Friday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock fall -1.53% to $26.39. Over the last five days, the stock has gained 6.84%. Beam Therapeutics Inc shares have risen nearly 6.41% since the year began. Nevertheless, the stocks have fallen -5.62% over the past one year. While a 52-week high of $49.50 was reached on 01/07/25, a 52-week low of $20.84 was recorded on 01/02/25. SMA at 50 days reached $26.35, while 200 days put it at $25.46.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 25.64, which if violated will result in even more drops to 24.88. On the upside, there is a resistance level at 27.10. A further resistance level may holdings at 27.80. The Relative Strength Index (RSI) on the 14-day chart is 48.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.62%. Stochastics %K at 46.50% indicates the stock is a holding.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2024-12-13, dropping by -1.91 million shares to a total of 10.06 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 11.97 million shares. There was a decline of -18.99%, which implies that there is a negative sentiment for the stock.
